Duration of Testosterone Suppression after a 9.45 mg Implant of the GnRH-Analogue Buserelin in Patients with Localised Carcinoma of the Prostate. A 12-Month Follow-up Study

European Urology

Volumn 50, Issue 3, 2006, Pages 483-489

  Pettersson, Bill ^a   Varenhorst, Eberhard ^a   Petas, Anssi ^b   Sandow, Jürgen ^c  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Buserelin; GnRH analogue; Hot flushes; Neoadjuvant endocrine therapy; Potency; Prostate cancer; Radiation; Testosterone

Indexed keywords

BUSERELIN; TESTOSTERONE;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; CANCER RADIOTHERAPY; CASTRATION; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG RELEASE; EVALUATION; GONAD FUNCTION; HOT FLUSH; HUMAN; HYPOGONADISM; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BUSERELIN; CARCINOMA; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION ROUTES; DRUG IMPLANTS; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HOT FLASHES; HUMANS; IMPOTENCE; LIBIDO; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE; PROSTATIC NEOPLASMS; SEXUAL BEHAVIOR; TESTOSTERONE; TIME FACTORS;

EID: 33746868622     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.03.001     Document Type: Article

References (23)

1. Cook T., and Sheridan W.P. Development of GnRH antagonists for prostate cancer: new approaches of treatment. Oncologist 5 (2000) 162-168
2. Lee H.H.K., Warde P., and Jewett M.A.S. Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 83 (1998) 438-448
3. Forman J.D., Kumar R., Haas G., Montie J., Porter A.T., and Mesina C.F. Neoadjuvant hormonal downsizing of localised carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 13 (1995) 8-15
4. Shearer R.J., Davies H.J., Gelister J.S.K., and Dearnaley D.P. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 69 (1992) 521-524
5. Potosky A.L., Knopf K., CleggLX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes group. J Clin Oncol 19 (2002) 3750-3757
6. Pilepich M.V., Krall J.M., Al-Sarraf M., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology group. Urology 45 (1995) 616-623
7. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 819-821
8. Paule B. Reappraisal of the concept of hormone therapy in metastatic prostate cancer and implications for treatment. Eur Urol 47 (2005) 729-735
9. Hirano D., Okada Y., Minei S., Minei S., Takimoto Y., and Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45 (2004) 586-592
10. Oefelein M.G. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 160 (1998) 1685-1688
11. Nejat R.J., Rashid H.H., Bagiella E., Katz A.E., and Nenson M.C. A prospective analysis of time to normalisation of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164 (2000) 1891-1894
12. Dearnaley D.P., Norman A.R., and Shahidi M. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter; comment). J Urol 162 (1999) 170
13. Pickles T., Agranovich A., Berthelet E., et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94 (2002) 362-367
14. Meinhardt W., and Horenblas S. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter; comment). J Urol 162 (1999) 170-171
15. Gulley J.L., Figg W.D., Steinberg S.M., Carter J., Hussain M.H., and Dahut W.L. A prospective analysis of the time to normalisation of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 173 (2005) 1567-1571
16. Spetz A.C., Hammar M., Lindberg B., Spangberg A., Varenhorst E., and the Scandinavian prostate cancer group-5 trial study. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 166 (2001) 517-520
17. Wijma C., Varenhorst E., Hjertberg H., et al. Patienten kan bestämma själv: medicinsk eller kirurgisk behandling (summary in English). [Prostate cancer study: patients may choose for themselves between medical or surgical treatment.]. Läkartidningen 89 (1992) 1659-1661
18. Blom J.H.M., Hirdes Wh, Schroeder F.H., et al. Pharmacokinetics and endocrine effects of the LHRH analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. Urol Res 17 (1989) 43-46
19. Sandow J., Seidel G., Rechenberg W., Jerabek-Sandow G., and Krauss B. Implants and other controlled release systems for long-term LHRH agonist administration. In: Filicori M., and Flamigni C. (Eds). Treatment with GnRH analogues: controversies and perspectives (1996), Parthenon Publishing, London 60-63
20. Suprefact Depot product information. Available at: http://www.mpa.se/spc_pil/pdf/enhumspc/Suprefact%20Depot%20implant%209.45%20mg%20ENG.pdf#search='suprefact%20depot'.
21. Griffiths K. Is there a best castration?. Cancer 72 (1993) 3807-3809
22. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
23. ®?. Eur Urol Suppl 4 8 (2005) 30-36